Assay News and Research

RSS

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.

From QIAGEN Manchester Limited 18 Jun 2015

Highly efficient ChIP assay kit for FFPE samples

Chromatrap®, a business unit of Porvair Sciences, has introduced a new Formaldehyde Fixed Paraffin-Embedded (FFPE) ChIP Kit which overcomes the widely acknowledged shortfalls of the technique.

From Chromatrap® - Porvair Sciences Ltd 17 Jun 2015

Optimised ChIP protocols for qPCR and sequencing

Chromatrap®, a business unit of Porvair Sciences, has announced a new web page that brings together protocols developed using their proprietary solid state chromatin immunoprecipitation (ChIP) technology.

From Chromatrap® - Porvair Sciences Ltd 17 Jun 2015

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development.

17 Jun 2015

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of idarucizumab, an investigational agent, in reversing the anticoagulant effect of dabigatran in healthy volunteers. The data demonstrate that complete reversal was achieved following administration of idarucizumab.

17 Jun 2015

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Ventana Medical Systems, Inc., a member of the Roche Group, today announced approval of the VENTANA ALK (D5F3) CDx Assay by the US Food and Drug Administration as a companion diagnostic to aid in the identification of patients for Pfizer's FDA approved targeted therapy, XALKORI (crizotinib).

15 Jun 2015

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization.

15 Jun 2015

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that clinical data featuring its Precision Cancer MonitoringSM platform will be presented at the 2015 Cancer Markers and Liquid Biopsies conference in San Diego, CA on June 11-12, and at the AACR Precision Medicine Series: Integrating Clinical Genomics and Cancer Therapy in Salt Lake City, UT on June 13-16.

8 Jun 2015

New therapeutic target discovered for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease for which as yet no causal therapy exists. It is, however, known that the lung interstitium - the connective tissue between the air sacs in the lower part of the lung - is affected.

8 Jun 2015

Profil Institute for Clinical Research forms strategic partnership with Gubra

Profil Institute for Clinical Research, an clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today a strategic collaboration with Gubra ApS, a metabolic preclinical and drug discovery company, to combine expertise and resources to discover and translate into clinical research novel drug targets, compounds and biomarkers addressing metabolic disease.

4 Jun 2015

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Researchers have shown that a novel delivery strategy can efficiently introduce a functional microRNA that has anti-cancer and angiogenic activities into two different types of cells--breast cancer cells to inhibit tumor growth and metastasis, and cells that line blood vessels to protect against atherosclerosis.

4 Jun 2015

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

Aushon BioSystems, a leading provider of products and services for multiplex quantitative detection of protein biomarkers, today announced the commercial release of its Ultrasensitive Cira Assays capable of measuring concentrations of low abundance proteins down to the femtogram/mL level.

2 Jun 2015

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Astellas Pharma Inc. announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced androgen receptor (AR) positive, triple-negative breast cancer (TNBC) were presented during an oral abstracts session at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

2 Jun 2015

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015.

2 Jun 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Researchers identify 763 proteins in human aqueous humor that nourish the cornea and the lens

Researchers conducting a comprehensive proteomics analysis of human aqueous humor samples identified 763 proteins - including 386 proteins detected for the first time - in this clear fluid that helps maintain pressure in the eye and nourishes the cornea and the lens.

30 May 2015

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

Halozyme Therapeutics, Inc. and Ventana Medical Systems, Inc., a member of the Roche Group, announced today a global agreement to collaborate on the development of, and for Ventana to ultimately commercialize, a companion diagnostic assay for use with Halozyme's investigational new drug, PEGPH20

30 May 2015

UH researchers identify new method to provide diagnostic information on kidney disease

University of Houston researchers have identified a new, less-invasive method to provide diagnostic information on kidney disease and its severity.

30 May 2015

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Immunotherapy with the anti-PD-1 antibody pembrolizumab (Keytruda) was effective in one out of four patients with recurrent or metastatic head and neck cancer, according to results presented at the 2015 meeting of the American Society for Clinical Oncology.

30 May 2015

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Guardant Health today announced that five abstracts submitted by the University of California, San Francisco; University of California, San Diego; and MD Anderson highlighting the performance and clinical utility of Guardant360 have been accepted for oral and poster presentations at the 2015 American Society of Clinical Oncology Annual Meeting in Chicago, May 29-June 2.

27 May 2015

Assay News and Research

Hitachi High-Technologies, QIAGEN form new strategic partnership to advance molecular testing

Highly efficient ChIP assay kit for FFPE samples

Optimised ChIP protocols for qPCR and sequencing

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

VENTANA ALK (D5F3) CDx Assay receives FDA approval

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

Clinical data of Trovagene's Precision Cancer Monitoring platform to be presented at two medical conferences

New therapeutic target discovered for idiopathic pulmonary fibrosis

Profil Institute for Clinical Research forms strategic partnership with Gubra

Novel strategy shows aptamer-based modular delivery of microRNA in endothelial, breast cancer cells

Aushon BioSystems announces commercial release of Ultrasensitive Cira Assays

Enzalutamide Phase 2 study for AR positive triple-negative breast cancer meets primary endpoint

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Researchers identify 763 proteins in human aqueous humor that nourish the cornea and the lens

Ventana, Halozyme partner to develop companion diagnostic assay for cancer treatment

UH researchers identify new method to provide diagnostic information on kidney disease

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Clinical utility data for Guardant360 platform to be presented at ASCO 2015

Microplate-based assays in microbiology research eBook eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News